Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu) Novel TAL1 targets beyond protein-coding genes: identification of TAL1-regulated microRNAs in T-cell acute lymphoblastic leukemia The basic helix-loop-helix transcription factor TAL1 is aberrantly expressed in a majority of T-cell acute lymphoblastic leukemia (T-ALL) cases characterized by arrested development in the thymic late cortical stage.
1,2 Although TAL1 is a bona fide T-cell oncogene, 3 with known direct targets in T-ALL, 4 the aberrant transcriptional circuitry responsible for thymocyte transformation is not yet fully understood. MicroRNAs are small, non-coding RNAs that function as endogenous post-transcriptional repressors of protein-coding genes by binding to target sites in the 3 0 -UTR of messenger RNAs. 5 Aberrant expression of these molecules has been reported in several hematological malignancies, and microRNA expression signatures delineate ALL subgroups 6 and can be interpreted in light of their variation during hematopoiesis. 7 Individual microRNAs and networks have been implicated in T-ALL, 8 but the mechanisms responsible for altered microRNA expression in this malignancy remain poorly explored. Here, we report the identification of novel, non-protein-coding TAL1 target genes, implicating microRNA genes as part of the transcriptional network downstream of TAL1 that may be putatively involved in its oncogenic properties.
To identify a TAL1-dependent microRNA gene expression profile, we ectopically expressed TAL1 in the TAL1-negative T-ALL cell line P12 and performed low-density array analysis (see Supplementary Data online for materials and methods). From 204 detected microRNAs (out of 372 analyzed), we identified eight whose expression changed significantly upon TAL1 overexpression (Figure 1a and Supplementary Tables 1 and 2 ). Subsequent validation was performed by quantitative PCR analysis of each microRNA after enforcing or silencing the expression of TAL1. This allowed us to confirm the expected TAL1-mediated regulation for five microRNAs: namely, miR-135a, miR-223 and miR-330-3p as being upregulated by TAL1; and miR-146b-5p and miR-545 as being downregulated (Figures 1b-f) . The three remaining microRNAs were excluded from subsequent analyses, as we stringently considered only those genes to be validated whose expression was regulated in the predicted manner upon both TAL1 overexpression and silencing (data not shown).
Next, we evaluated whether the validated microRNAs were direct targets of TAL1 in T-ALL cells. For this purpose, we scrutinized publicly available TAL1 ChIP-seq data (GEO accession number GSE29181) for two T-ALL cell lines (JURKAT and CCRF-CEM) and two primary T-ALL samples 4 for the presence of TAL1-binding peaks up to 10 kb upstream of the transcription start site of each microRNA gene. We identified one peak in a putative promoter region for miR-146b (Supplementary Figure 1a) , suggesting that this gene may be a transcriptional target of TAL1. Furthermore, two peaks were observed upstream of miR-223 transcription start site (Supplementary Figure 1b) . To confirm these findings, we performed TAL1 ChIP-quantitative PCR in JURKAT and CCRF-CEM cells using primers designed for the genomic areas covered by the two peaks in the miR-223 locus. We confirmed that there is more than twofold enrichment, as compared with a mock ChIP performed against fibrillarin, in the amplified area within 3.5 kb upstream of the miR-223 transcription start site (Figure 1g ). These results indicate that miR-223 is a direct target of TAL1 in T-ALL. Interestingly, TAL1 appears to bind to a previously described region containing a conserved proximal genomic element with possible binding sites for the transcription factor C/EBP. 9 We did not find evidence from the available TAL1 ChIP-seq data for direct binding of TAL1 to the remaining microRNA genes, suggesting that miR-135a, miR-330-3p and miR-545 are indirectly regulated by TAL1, at least in the T-ALL cells analyzed.
Interestingly, analysis of microRNA gene expression profiles in different T-ALL subsets 8 revealed that TAL/LMO primary samples (integrating Sil-Tal1 þ and LMO þ cases, which frequently express high TAL1 levels) display higher levels of miR-223 (P ¼ 0.035) and tend to express lower levels of miR-146b-5p (P ¼ 0.092) than other Figure 2) . In line with these observations, miR-223 appears to follow the same pattern of expression along normal human thymocyte development as TAL1, 10 with high levels in CD34 þ T-cell precursors and sharp downregulation in more differentiated subsets (Supplementary Figure 3a) . A similar pattern was observed for miR-135a (Supplementary Figure 3b) , in agreement with the notion that TAL1 positively regulates both genes. In contrast, miR-146b-5p is clearly upregulated in the double-positive to single-positive transition and is amongst the most upregulated microRNAs in mature, single-positive thymocytes. 11 The fact that miR-146b-5p levels associate with thymocyte maturation (Supplementary Data from the analysis of congruent putative interactions between known TAL1-regulated protein-coding genes and the validated microRNA genes are in line with the notion that the latter could be part of downstream networks collaborating in TAL1-mediated leukemogenesis (Figure 2) . Indeed, most TAL1-upregulated genes that have 3 0 -UTRs predicted as targets for the TAL1-downregulated miR-146b-5p and -miR-545 have a known or putative oncogenic function (Figure 2a ). For example, CD53 was shown to protect JURKAT cells from apoptosis, PDE3B appears to be involved in glucocorticoid resistance in CEM cells and ETS-1 participates in the T-cell maturation arrest mediated by TLX genes in T-ALL (see Supplementary Table 3 for details and references). Interestingly, the T-ALL-associated oncogene MYB was recently shown to be a direct TAL1 target forming a feed-forward loop involved in the TAL1-dependent leukemogenic program. 4 Our bioinformatics analyses now raise the possibility that TAL1 may reinforce MYB upregulation by inhibiting the expression of miR-545. Also of note, three of the four genes (KRT1, Rapgef5, JAZF1) with predicted 3 0 -UTR seed sequences for both miR-146b-5p and miR-545 are associated with protumoral functions (Supplementary Table 3 ). In sharp contrast, the TAL1-downregulated genes that are predicted targets for miR-135a, miR-223 and miR-330-3p display a clear abundance in (putative) tumor suppressors or in genes whose functions are compatible with antitumoral effects (Figure 2b and Supplementary Table 4) . This is evident, for instance, in the case of the four genes potentially regulated by two microRNAs, in which only one has an oncogenic role (IGF1R) and three likely have tumor-suppressive functions (SRGAP3, TOX, LRP12).
Circumscription of our analysis to validate target genes of each microRNA, followed by gene set enrichment analysis showed an enrichment in biological processes related to inflammation (e.g., NF-kB signaling pathway and IL1/IL1R signaling pathway) and cancer (e.g., pathways in cancer), as detailed in Supplementary Table 5 and Supplementary Table 6 . Interestingly, the validated targets for the TAL1-downregulated gene of miR-146-5p include IRAK1, TRAF6 and NFKB1 (all of which are involved in chronic inflammation), as well as the oncogene KIT (Supplementary Table 5 and Supplementary Figure 5) . In contrast, miR-330-3p, upregulated by TAL1, reportedly targets E2F1 and CDC42, both of which are described to promote apoptosis in different cell types, including Jurkat cells. MiR-223 is a myeloidspecific microRNA essential for normal neutrophil maturation, and responsible for granulocyte differentiation and negative regulation of progenitor proliferation via MEF2C downregulation. 12 In agreement, miR-223 functions as a tumor suppressor in acute myeloid leukemia, 13 and appears to be repressed in chronic myeloid leukemia, allowing for the expression of MEF2C.
14 In contrast, miR-223 is frequently overexpressed in T-ALL, cooperating with NOTCH1 to accelerate the onset of disease in a Notch-induced Tables 3 and 4 . 'Tumor suppressor-like': bona fide or putative tumor suppressors or genes that have proapoptotic, antiproliferative or prodifferentiating roles; 'Oncogene-like': bona fide or putative oncogenes or genes that have antiapoptotic or proliferative roles. 'Undetermined': genes with undetermined function or whose role in cancer remains unknown. leukemia mouse model. This effect was proposed to be due, at least in part, to inhibition of FBXW7, a negative regulator of Notch signaling. 8 However, FBXW7 targets the degradation of other oncogenic proteins, such as c-Myc and mTOR, and the expression of miR-223 is significantly elevated in TAL1-positive T-ALL cases (Supplementary Figure 2) , suggesting that the oncogenic function of this microRNA may extend beyond mere collaboration in Notchinduced leukemia. Moreover, the proleukemic role of mir-223 may be also achieved by downregulating targets such as E2F1, FOXO1, RHOB or EPB41L3, which have been associated with induction of apoptosis and/or have tumor-suppressive roles (Supplementary  Table 5 ). Interestingly, the intriguing possibility that miR-223 may potentially act downstream of TAL1 to negatively regulate MEF2C, recently identified as an oncogene in T-ALL, 15 would be in line with the observations that TAL1 and MEF2C tend to segregate, defining two discrete T-ALL subsets. 15 In summary, our studies identify and validate for the first time a small set of TAL1-regulated microRNA genes whose role may be important in the context of hematopoiesis and T-cell leukemogenesis. a post-doctoral grant from FWO Vlaanderen. We would like to thank Steve Lefever for primer design. 
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